Good morning :)
Place Order
Add to Watchlist

Dishman Carbogen Amcis Ltd

DCAL

Dishman Carbogen Amcis Ltd

DCAL
Health CareLabs & Life Sciences Services
SmallcapWith a market cap of ₹3,731 cr, stock is ranked 871
High RiskStock is 4.42x as volatile as Nifty
234.801.34% (-3.18)
234.801.34% (-3.18)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CareLabs & Life Sciences Services
SmallcapWith a market cap of ₹3,731 cr, stock is ranked 871
High RiskStock is 4.42x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Avg

The stock has a moderate number of red flags

How to use scorecard? Learn more

Health CareLabs & Life Sciences Services
SmallcapWith a market cap of ₹3,731 cr, stock is ranked 871
High RiskStock is 4.42x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
-21.440.66
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
50.356.430.53%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Dishman Carbogen Amicis Limited is an India-based contract research and manufacturing services (CRAMS) company. The Company is engaged in the process of research and development to late-stage clinical and commercial manufacturing

Investor Presentation

View older 

Nov 13, 2024

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 4.59%, vs industry avg of 4.51%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 17.23% to 15.01%

Loading...

Financial YearFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue1,739.821,740.482,112.422,088.061,950.482,184.112,440.692,643.982,639.91
Raw Materialssubtract329.58402.19378.01476.38434.77460.50630.40601.212,350.20
Power & Fuel Costsubtract49.4748.3356.1460.2641.8762.7387.83104.31
Employee Costsubtract596.02625.40714.64762.27872.91981.491,029.861,208.16
Selling & Administrative Expensessubtract147.69136.29190.73124.58113.81147.71197.66205.53
Operating & Other expensessubtract138.4737.23167.18122.55196.60171.53183.12216.20
Depreciation/Amortizationsubtract213.50211.42240.38282.87307.94307.59280.72310.86308.05
Interest & Other Itemssubtract49.0148.8356.5561.9547.6156.8185.69119.97132.59
Taxes & Other Itemssubtract70.6576.2298.4638.69100.10-22.26-24.7931.1923.10
EPS19.1513.039.96-10.531.15-1.90-9.79-11.10
DPS1.200.000.200.000.000.000.000.000.00
Payout ratio0.000.020.000.000.000.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2021

Annual report

PDF

Investor Presentation

May 12PDF
FY 2022

Annual report

PDF

Investor Presentation

May 11PDF
Feb 4PDF
Oct 28PDF
Aug 12PDF
FY 2023

Annual report

PDF

Investor Presentation

May 23PDF
Feb 10PDF
Nov 11PDF
Aug 9PDF
FY 2025

Annual Report Pending

Investor Presentation

Nov 13PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CareLabs & Life Sciences Services

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Dishman Carbogen Amcis Ltd-24.310.66
Divi's Laboratories Ltd100.7511.880.49%
Syngene International Ltd71.638.580.14%
Aarti Pharmalabs Ltd26.173.230.48%

Price Comparison

Compare DCAL with any stock or ETF
Compare DCAL with any stock or ETF
DCAL
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding59.32%1.03%0.20%8.17%31.28%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep8.90%8.80%8.61%8.70%8.04%8.17%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Dishman Carbogen Amcis Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
HSBC Flexi Cap Fund - Growth - Direct Plan

Growth
0.7911%0.58%-0.02%87/97 (-5)
Motilal Oswal Nifty Microcap 250 Index Fund - Growth - Direct Plan

Growth
0.0777%0.17%-0.01%153/310 (-17)
Bandhan BSE Healthcare Index Fund Direct Plan-Growth

Growth
0.0005%0.10%0.10%74/102 (+5)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

DCAL has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 12, 2019

Final
Final | Div/Share: ₹0.20

Dividend/Share

0.20

Ex DateEx Date

Sep 12, 2019

News & Opinions
Earnings
Dishman Carbogen Amcis reports consolidated net profit of Rs 33.09 crore in the September 2024 quarter

Net profit of Dishman Carbogen Amcis reported to Rs 33.09 crore in the quarter ended September 2024 as against net loss of Rs 40.90 crore during the previous quarter ended September 2023. Sales rose 34.51% to Rs 789.04 crore in the quarter ended September 2024 as against Rs 586.59 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales789.04586.59 35 OPM %18.6510.37 - PBDT117.1741.83 180 PBT45.08-33.21 LP NP33.09-40.90 LP Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Dishman Carbogen Amcis to conduct board meeting

Dishman Carbogen Amcis will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Dishman Carbogen Amcis to conduct AGM

Dishman Carbogen Amcis announced that the 17th Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
Dishman Carbogen slumps on dismal Q1 results

On a consolidated basis, Dishman Carbogen Amcis reported net loss of Rs 77.57 crore in Q1 June 2024 as against net profit of Rs 17 crore in Q1 June 2023. Net sales declined 27.59% year-on-year to Rs 523.78 crore in Q1 June 2024. Net revenue was impacted mainly due to lower revenue in Switzerland and Netherlands. Pre-tax loss stood at Rs 77.56 crore in Q1 June 2024 as against pre-tax profit of Rs 29.49 crore in Q1 June 2023. EBITDA slumped 76.8% YoY to Rs 29.39 crore in Q1 June 2024. EBITDA margin stood at 5.6% in Q1 June 2024, lower than 17.5% in Q1 June 2023. This was primarily due to lower operating margins in its European subsidiaries, Carbogen Amcis AG and Carbogen Amcis BV. Factors contributing to this decline include delays in high-margin project realization, increased sales of lower-margin cholesterol products, and higher raw material costs. Additionally, the company incurred a larger operating loss in its French operations compared to the previous year. During the quarter, cost of goods sold (COGS) fell 59.4% YoY to Rs 66.35 crore while employee expenses rose 7.3% YoY to Rs 316.82 crore. Carbogen Amcis AG ' CRAMS revenue decreased by 39.6% YoY in Q1 FY25 primarily due to shifting of a major development project and deferment of shipment of a commercial batch to the next quarters. This had an impact of CHF 9.8 m in revenue and CHF 3.92 m in operating profit due to timing difference. Carbogen Amcis BV' Cholesterol and Vitamin D analogues revenue decreased by 16.4% YoY in Q1 FY25 primarily due to lower sales of Vitamin D analogs by 38%. This is expected to pick up in revenue in the remainder part of the year. DCAL India ' NCE APIs and Intermediates revenue increased by 114.5% YoY in Q1 FY25 primarily due to increase in commercial supplies from Bavla site after the EDQM clearance. DCAL India ' Quats & Generics revenue decreased by 20.4% YoY in Q1 FY25 primarily due to slow down in agrochemical sector, which is expected to pick up in the second half of the year. Dishman Carbogen Amcis is a fully integrated CRAMS (Contract Research & Manufacturing) company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing and supply of API to innovator pharmaceutical companies. The company has global presence with development and manufacturing sites in Switzerland, UK, France, Netherlands, India and China. Powered by Capital Market - Live

3 months agoCapital Market - Live
Spotlight
Dishman Carbogen Amcis Ltd leads losers in 'A' group

Piramal Enterprises Ltd, Redtape Ltd, Kaveri Seed Company Ltd and HEG Ltd are among the other losers in the BSE's 'A' group today, 14 August 2024.Dishman Carbogen Amcis Ltd crashed 11.40% to Rs 173.3 at 14:46 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 1.41 lakh shares were traded on the counter so far as against the average daily volumes of 87555 shares in the past one month.Piramal Enterprises Ltd tumbled 10.31% to Rs 884.1. The stock was the second biggest loser in 'A' group.On the BSE, 3.45 lakh shares were traded on the counter so far as against the average daily volumes of 72683 shares in the past one month.Redtape Ltd lost 8.07% to Rs 630.95. The stock was the third biggest loser in 'A' group.On the BSE, 6817 shares were traded on the counter so far as against the average daily volumes of 5678 shares in the past one month.Kaveri Seed Company Ltd shed 7.55% to Rs 1029.9. The stock was the fourth biggest loser in 'A' group.On the BSE, 12629 shares were traded on the counter so far as against the average daily volumes of 29328 shares in the past one month.HEG Ltd corrected 6.99% to Rs 2015.85. The stock was the fifth biggest loser in 'A' group.On the BSE, 21260 shares were traded on the counter so far as against the average daily volumes of 12450 shares in the past one month.Powered by Capital Market - Live

3 months agoCapital Market - Live
Earnings
Dishman Carbogen Amcis reports consolidated net loss of Rs 77.57 crore in the June 2024 quarter

Net loss of Dishman Carbogen Amcis reported to Rs 77.57 crore in the quarter ended June 2024 as against net profit of Rs 17.00 crore during the previous quarter ended June 2023. Sales declined 27.59% to Rs 523.78 crore in the quarter ended June 2024 as against Rs 723.38 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales523.78723.38 -28 OPM %5.5316.85 - PBDT-1.5399.94 PL PBT-72.1229.49 PL NP-77.5717.00 PL Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Dishman Carbogen Amcis announces board meeting date

Dishman Carbogen Amcis will hold a meeting of the Board of Directors of the Company on 13 August 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live

Cholamandalam Financial Holdings Ltd leads gainers in ‘A’ group

4 months agoBusiness Standard

Dishman Carbogen Q4 earnings effect: Shares plunge 12% in early trade, top losers on BSE

1 year agoBusiness Today

Dishman Carbogen declines 10% after Q4 loss widens

1 year agoMoneycontrol